European Journal of Medical Research - Deutsche AIDS ...

112 EUROPEAN JOURNAL OF MEDICAL RESEARCH
June 27, 2007
(23/45) at week 12, the rate of those being dissatisfied or very
dissatisfied was 26% (11/42) and 20% (9/45), respectively.
Conclusions: Experience within the program suggests that
improvement in satisfaction of enfuvirtide patients with therapy
may be achieved by a structured training and experience
exchange program. Detailed repeated instruction and support
may lead to increased treatment acceptance and improved adherence.
1. Lalezari J-P et al. New England J of Med., Vol 348, 22 2003
2 Foy K et al. J of the Assoc. of Nurses in Aids Care, Vol 16, 2
2005
D.83 (Vortrag)
Gesundheitstrainings HIV/AIDS - a nationwide
structured patient education program for people
living with HIV/AIDS in Germany
Klumb S. 1 , Dannecker M. 1 , Gronski H. 1 , Schafberger A. 1
1 Verein Gesundheitstraining HIV/AIDS e.V., Berlin, Germany
Background: In 1998 a working group of HIV+ patients and
treatment advocates started to develop a structured patient education
program for people living with HIV/AIDS in Germany.
From our perspective adherence is a consequence of
psychosocial factors and processes.
From July 2005 on eight patient trainings have been conducted,
61 patients were included. Trainings have been conducted
in groups. Group size varied (mean 10.1, range 5 - 12).
Mean age was 41.2 years. 15.1 % of participants were female
84.9 % male.
Two types of research have been conducted resp. are ongoing:
an evaluation of the curricula and the qualification of
trainers (completed), and an evaluation of health economic
consequences and long lasting effectiveness (still ongoing).
Methods: The research utilized questionnaires several times
during the program and 6 month after the last training session.
In addition two group discussions leaded by the researchers
were conducted as qualitative part.
The second part of the research used two questionnaires
(MOS-HIV and HADS) and collected “hard data” via self report
and patients’ health insurance companies. Questionnaires
and data collection was carried out after inclusion but before
the first training session and 12 month after the last training
session.
Results: 41 patients were included in this OT-style analysis
(LOF = 2, 18 did not fill out the last or any other questionnaire).
Six month after the last training session 53.7 % (n =
22) stated, that the patient education program has been very
helpful and 41.5 % (n = 17) that it has been helpful in terms
of living with HIV. Only 2.4 % respectively stated the intervention
has been somewhat (n = 1) or not helpful (n = 1).
Table 1
The 95.2 % (n = 39) patients gave the following key topics
as most valuable:
1. exchange of experience (n= 21)
2. develop a new (different) view of living with HIV (more
self confidence/ less anxiety / improved QoL) (n= 16)
3. information / diet / sport / coping with stress (n = 12)
4. HAART / management of side effects / therapeutic options
and strategies (n = 11)
5. due to knowledge and training a more specific / focussed
decision-making (n = 7)
More detailed data and the results of ongoing evaluation of
“hard data” will be provided.
D.84 (Poster)
Health related quality of life changes in
antiretroviral naïve HIV-infected patients on
Atazanavir based regimens: Week 48 results from
AI424-089
Iloeje U. 1 , Kastango K. 1 , Malan N. 2 , David N. 3 ,
Krantz E. 4 , Reeb I. 5 , Nakonz T. 5 , Matthew M. 1 ,
Frederick D. 6 , Hammond J. 6
1 Bristol-Myers Squibb, Pharmaceutical Research Institute,
Wallingford, United States of America, 2 Triple M Research,
Port Elizabeth, South Africa, 3 Brooklyn Medical Research
Center, Cape Town, South Africa, 4 Quinta-Research,
Bloemfontein, South Africa, 5 Bristol-Myers Squibb
GmbH&Co.KGaA, Munich, Germany, 6 Bristol-Myers Squibb,
Wallingford, United States of America
Background: HRQoL declines in HIV-infected patients in
the absence of effective therapy or with older more symptomatic
ARV regimens. Atazanavir is potent and well tolerated
as a once daily protease inhibitor within a HAART regimen.
Data on HRQoL in treatment naïve patients on ATV/r or ATV
regimens are limited.
Methods: In AI424-089 (a randomized open label study comparing
ATV/r 300mg/100mg with ATV 400mg, both in combination
with 3TC and extended-release d4T) HRQoL was assessed
using the EQ-5D questionnaire, and the MOS-HIV, a
disease specific questionnaire. HRQoL was assessed at baseline,
Week 24 and 48. Primary endpoints were the physical
(PHS) and mental (MHS) summary scores (mean score
50±10) for the MOS-HIV; and the health index score (HIS,
range 0-1), and visual analogue scale (VAS, range 0-100) for
the EQ-5D. Clinically important changes include a 2 point
change (MOS-HIV summary scores) and 0.03 change (EQ-5D
HIS). Primary outcomes were changes in scores from baseline.
Results: Of 199 treated subjects, ~88% of the subjects completed
the EQ-5D and ~75% of the subjects completed the
MOS-HIV at Weeks 24 and 48 (Table 1).